Israeli startup Polyrizon has developed a technology platform to produce biological gels
Polyrizon is a startup dedicated to “Health Care” and is in its first phase business, which develops new gel-based biological technology called C & C (capture and hold).
C & C technology with unique and specific capabilities can be readily adapted to a wide range of applications to protect the human body from pathogens such as pollen, viruses, bacteria, and more. Polyrizon has developed a core platform technology to produce biological protective gels that act as a physical/chemical barrier to pathogens such as allergens, viruses, bacteria, fungi and other. Polyrizon technology is used to attract specific pathogens within the body using the gel as a coating in the area of the nasal mucosa.
The Gel Capture and Contain Pathogenic particles encountered to human mucosal membranes; it prevents these particles from reaching target cells and activating the immune response. The gel containing the mentioned particles is then removed from the body via natural processes.
Polyrizon’s versatile platform technology has the potential to be applied for protection against a variety of allergens, toxins, and other harmful substances. The Company’s initial target is the enormous allergy market, where there is a clear need and growing awareness of the advantages of allergy prevention. Other markets include the vaginal viral infection market, biodefense, dermatology and common respiratory infections.